Skip to main content

Electra Therapeutics, Inc.

ETRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002088082

In the last 90 days, Electra Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Key figures

Insider buysLast 90 days, $20.0M in total
1
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026
0
13F valueReported value at the end of Q2 2026
$0
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding ETRA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ETRA at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Electra Therapeutics, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 23, 2026 (view filing)5:35 PM ETSep 212 daysGordon Carl LDirector, 10% OwnerPPurchase+1.33M$15.00+$20.0M+313.8%1.76M after2 lotsDuplicate filing
Sep 23, 2026 (view filing)5:29 PM ETSep 212 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+1.33M$15.00+$20.0M+313.8%1.76M after2 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in Electra Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

View all: Top 10 13F holders, Q2 2026

No institution reported holding ETRA in 13F filings for Q2 2026.